Effect of virtual reality intervention on hospitalized patients with acute pain after thoracoscopic surgery: a pilot randomized clinical trial.
Weibo Cao, Fan Ren, Tong Li, Fei Ma, Yuan Shi, Xuanguang Li, Cancan Cao, Ning Zhou, Hanyi Li, Haochuan Yu, Fuling Mao, Gang Chen, Lingling Zu, Li Wei, Qing Li, Yuanyuan Zhang, Lin Su, Wei Cui, Li Wu, Yuxin Zheng, Jing Li, Chunyan Wang, Renhua Ju, Chongliang Fang, Ling Yin, Yi Lu, Qiang Zhang, Song Xu
Int J Surg 111(3) 2752-2756
摘要
摘要
The study investigates the effectiveness of immersive virtual reality (VR) as a nonpharmaceutical approach to manage postoperative pain in patients following thoracoscopic surgery. In this single-center, triple-arm pilot randomized controlled trial (RCT), 61 postsurgical patients with a postoperative pain numerical rating scale (NRS) score ≥4 after receiving standard analgesia were included and assigned to either a quantum clinics-VR (QTC-VR) group, a Placebo-VR group, or a control group. The QTC-VR group engaged in a daily 10-minute interactive pain relief 3D-VR program, while the Placebo-VR group watched a daily 10-minute relaxation-based 2D film through VR headsets for three days following surgery. 61 postsurgical patients were randomized and allocated (21 in the QTC-VR group, 20 in the Placebo-VR group, and 20 in the control group) in the final intention-to-treat (ITT) analyses. Compared with patients receiving Placebo-VR intervention, patients reported significantly lower pain scores following the daily QTC-VR intervention on postoperative days 1 (mean difference, -0.889; 95% CI, -1.464 to -0.314; P < 0.001), 2 (mean difference, -0.631; 95% CI, -1.211 to -0.051; P = 0.014), and 3 (mean difference, -0.798; 95% CI, -1.345 to -0.251; P < 0.001), respectively. Additionally, patients receiving QTC-VR intervention also reported high satisfaction and tolerable adverse events with their treatment. In conclusion, this pilot RCT demonstrates that QTC-VR might be a promising intervention for pain management post-thoracoscopic surgery, warranting further validation in ongoing phase III trials.
KM 提取结果
0 个 Figure · 0 个 KM 面板